Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

PR Newswire
December 27, 2021 — 18:45 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Beijing biotech Casino China Covid-19 healthcare Hong Kong JD finance Macau medicine taiwan United States Vaccine

Related News:

The 9th Asian Winter Games takes place

February 8, 2025 — 19:58

Vietnam Makes Top 5 Debut in Agoda’s 16th Gold Circle Awards, Celebrating Hospitality Excellence

January 28, 2025 — 11:00

Altair Engineering Inc. Stockholders Approve Proposed Merger with Siemens

January 23, 2025 — 05:05

BICV’s Debut at CES 2025: Showcasing Full-Stack, All-Domain Products on the International Stage

January 9, 2025 — 22:03

JSAUX Debuts at CES 2025, Showcases Innovative FlipGo Portable Monitor

January 5, 2025 — 12:00

Evolving Global Asset Management Industry in Focus at Asset Abu Dhabi

December 11, 2024 — 02:10

Crystal clear: Pingcheng period glassware of Northern Wei Dynasty

November 9, 2024 — 08:00

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

November 8, 2024 — 17:45

LPS Launches NeuroNode: Empowering Advanced AI for Enterprises with On-Premises LLM

November 7, 2024 — 17:39

Franchising and Licensing Asia (FLAsia) 2024